Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods.
Pieper KS, Tsiatis AA, Davidian M, Hasselblad V, Kleiman NS, Boersma E, Chang WC, Griffin J, Armstrong PW, Califf RM, Harrington RA. Pieper KS, et al. Circulation. 2004 Feb 10;109(5):641-6. doi: 10.1161/01.CIR.0000112570.97220.89. Circulation. 2004. PMID: 14769687
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes.
Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, Moliterno DJ, Lincoff AM, Armstrong PW, Van de Werf F, Califf RM, Harrington RA. Rao SV, et al. Among authors: pieper ks. J Am Coll Cardiol. 2006 Feb 21;47(4):809-16. doi: 10.1016/j.jacc.2005.09.060. Epub 2006 Jan 26. J Am Coll Cardiol. 2006. PMID: 16487850 Free article.
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ 3rd, Califf RM. White HD, et al. Among authors: pieper ks. Am Heart J. 2006 Dec;152(6):1042-50. doi: 10.1016/j.ahj.2006.08.002. Am Heart J. 2006. PMID: 17161049 Clinical Trial.
Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial).
Echols MR, Mahaffey KW, Banerjee A, Pieper KS, Stebbins A, Lansky A, Cohen MG, Velazquez E, Santos R, Newby LK, Gurfinkel EP, Biasucci L, Ferguson JJ, Califf RM. Echols MR, et al. Among authors: pieper ks. Am J Cardiol. 2007 Feb 1;99(3):315-21. doi: 10.1016/j.amjcard.2006.08.031. Epub 2006 Nov 30. Am J Cardiol. 2007. PMID: 17261389 Clinical Trial.
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial.
Mahaffey KW, Yang Q, Pieper KS, Antman EM, White HD, Goodman SG, Cohen M, Kleiman NS, Langer A, Aylward PE, Col JJ, Reist C, Ferguson JJ, Califf RM; SYNERGY Trial Investigators. Mahaffey KW, et al. Among authors: pieper ks. J Gen Intern Med. 2008 Mar;23(3):310-6. doi: 10.1007/s11606-007-0498-4. Epub 2008 Jan 15. J Gen Intern Med. 2008. PMID: 18196350 Free PMC article. Clinical Trial.
217 results